The firm recently advanced its first candidate into clinical testing, evaluating STX-1150 as a treatment for hypercholesterolemia.

Two separate research teams used base editing to make single-nucleotide changes in human embryos this month, targeting genes ...

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

Leishmaniasis cases are doubling at Ohio State's hospital as sand flies expand their range, while Dr. Satoskar prepares to ...

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to ...

Creative Biolabs is strengthening its lipid-based delivery portfolio with enhanced lipid nanoparticle (LNP) and liposome engineering capabilities designed to support the growing demand for RNA ...

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

Taxidermied, locked behind plexiglass and spinning slowly on a wooden dais in the National Museum of Scotland in Edinburgh, UK, the world’s most famous ewe remains a public spectacle three decades ...

ElevateBio industrializes cell and gene therapy manufacturing, using automation and AI to bring life-changing genetic ...

Developing novel ways to refine, reduce and replace the use of animals in research and enhance animal and human health.

Researchers have spent decades—and billions of dollars—sequencing animal and crop genomes, but fungi have historically been the forgotten middle child of genomics, only noticed when they&r ...

Prime Medicine, Inc. (NASDAQ:PRME) ranks among the overlooked penny stocks to buy right now, supported by strong upside ...